Codexis and Nestlé Health Science enter new health partnership
Protein engineering company Codexis, Inc has recently partnered with Nestlé Health Science in a large number of projects, such as the development of enzyme, CDX-6114 and management of phenylketonuria (PKU), an orphan metabolic disorder.
The deal will see Codexis receive an upfront payment of $14 million and potential milestones and royalties depending on product success. Codexis’ technology enables the implementation of biocatalytic solutions to meet customer needs. Nestlé Health Science will also receive access to the CodeEvolver protein engineering platform as part of the agreement.
Codexis will be eligible to receive clinical development, approval and commercial milestone payments related to CDX-6114 as well as tiered royalties on product sales. However, the company will remain responsible for the clinical development costs.
- Stryker sets its sights on Utah expansion
- Johnson & Johnson subsidiary is set to expand its manufacturing capabilities in Ireland
- GE Healthcare turns its focus on 3D printing and robotics
“This transaction validates our CodeEvolver protein engineering platform technology as a biotherapeutic discovery engine, and also highlights our ability to establish customized partnerships for unlocking the power of proteins with a growing list of the world’s great companies,” said John Nicols, Codexis President and Chief Executive Officer.
“Enzymes are key to healthy functioning. When enzymes are not present or not working properly there can be an impairment of a wide range of processes critical for human health,” commented Greg Behar, Chief Executive Officer of Nestlé Health Science.
“The partnership with Codexis strengthens our footprint in the enzyme field, a fast developing part of the nutritional therapy innovation frontier that is changing the way we manage our health.”
Family doctors should give COVID vaccine, survey finds
A new survey has found that doctors believe patients would be more open to receiving the COVID-19 vaccine if it was administered by a trusted doctor.
The research by Sermo, a social media network for clinicians, was carried out among 3,329 physicians from around the world. It found that nearly 70% said that if they could administer the vaccine to reluctant patients themselves, they believe they would feel more comfortable about getting vaccinated.
Additionally, nearly half of the people surveyed said that their ability to discuss the benefits of vaccination and answer patients' questions during appointments could help increase their willingness to get vaccinated.
The survey results are released as infection rates rise among people who have not received the vaccine. In the US Dr Rochelle Walensky, director of the US Centers for Disease Control and Prevention has called the latest surge "a pandemic of the unvaccinated".
Sermo’s COVID-19 Real Time Barometer also showed 65% of physicians believe that vaccinating children is essential for long-term control of the virus. Other findings include:
* 55% of physicians say their patients are more reluctant to vaccinate their children than themselves due to fear of adverse effects
* 60% believe a one-dose vial that administered at their office during appointments would be beneficial in continuing to administer vaccinations
* 81% believe that paediatricians and family doctors are in the best position to vaccinate children
Respondents also said resources and information should be created to educate their patient base and parents about the importance of getting vaccinated.
“Our survey reveals that physicians worldwide feel strongly that they can and perhaps, should, play a very important role in driving COVID vaccination uptake,” said Peter Kirk, Sermo's CEO.
“The trust they have built with their patients, combined with the ability to counsel, answer questions, ease concerns and provide assurances could help patients overcome their hesitancy to be vaccinated. Allowing physicians to vaccinate their own patients has the potential to increase vaccine rates.”